Combination stem cell therapy for the treatment of medically refractory coronary ischemia: A Phase I study

Cardiovascular Revascularization Medicine

Volumn 12, Issue 1, 2011, Pages 29-34

  Lasala, Gabriel P ^a   Silva, Jose A ^a   Kusnick, Barry A ^b   Minguell, Jose J ^a  

^a TCA Cellular Therapy   (United States)

^b Tchefuncte Cardiovascular Associates   (United States)

Author keywords

Combination cell therapy; Coronary ischemia; Stem cells

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERY OBSTRUCTION; ENDOTHELIAL PROGENITOR CELL; FEMALE; FUNCTIONAL STATUS; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYMAL STEM CELL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STABLE ANGINA PECTORIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; CELLS, CULTURED; CORONARY STENOSIS; ECHOCARDIOGRAPHY; ENDOTHELIAL CELLS; FEASIBILITY STUDIES; FEMALE; HUMANS; LOUISIANA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 78651418001     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2010.01.001     Document Type: Article

References (30)

1. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ Myocardial protection in reperfusion with postconditioning. Expert Rev Cardiovasc Ther 2005, 3:1035-1045.
2. Ferdinandy P, Schulz R, Baxter GF Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and post conditioning. Pharmacol Rev 2007, 59:418-458.
3. Cuevas P, Carceller F, Giménez-Gallego G Fibroblast growth factors in myocardial ischemia/reperfusion injury and ischemic preconditioning. J Cell Mol Med 2001, 5:132-142.
4. Yellon DM, Hausenloy DJ Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005, 2:568-575.
5. Sekiguchi H, Li M, Losordo DW The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol 2009, 219:235-242.
6. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belém L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003, 107:2294-2302.
7. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003, 361:47-49.
8. Briguori C, Reimers B, Sarais C, Napodano M, Pascotto P, Azzarello G, Bregni M, Porcellini A, Vinante O, Zanco P, Peschle C, Condorelli G, Colombo A Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J 2006, 151:674-680.
9. Beeres SL, Bax JJ, Dibbets-Schneider P, et al. Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am J Cardiol 2007, 100:1094-1098.
10. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009, 301:1997-2004.
11. Walter DH, Dimmeler S Endothelial progenitor cells: regulation and contribution to adult neovascularization. Herz 2002, 27:579-588.
12. Waksman R, Baffour R Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium. Cardiovasc Radiat Med 2003, 4:164-168.
13. Tse HF, Lau CP Therapeutic angiogenesis with bone marrow-derived stem cells. J Cardiovasc Pharmacol Ther 2007, 12:89-97.
14. Blau HM, Banfi A The well-tempered vessel. Nat Med 2001, 7:532-534.
15. Banfi A, von Degenfeld G, Blau HM Critical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep 2005, 7:227-234.
16. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006, 38:333-357.
17. Semenza GL Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007, 102:840-847.
18. Ganged K, Genève G, Amulet A, Bethalto C Endothelial-mural cell signaling in vascular development and angiogenesis. Arteriosclerosis Thromb Vasc Biol 2009, 29:630-638.
19. Covas DT, Panepucci RA, Fontes AM, Silva WA, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654.
20. Minguell JJ, Erices A, Conget P Mesenchymal stem cells. Exp Biol Med 2001, 226:507-520.
21. Caplan AI Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
22. Conget P, Minguell JJ Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999, 181:67-73.
23. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
24. Helisch A, Schaper W Arteriogenesis: the development and growth of collateral arteries. Microcirculation 2003, 10:83-97.
25. Schaper W Collateral circulation: past and present. Basic Res Cardiol 2009, 104:5-21.
26. Lasala GP, Minguell JJ Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction. Heart Lung Circ 2009, 18:171-180.
27. Benavente CA, Sierralta WD, Conget PA, Minguell JJ Subcellular distribution and mitogenic effect of basic fibroblast growth factor in mesenchymal uncommitted stem cells. Growth Factors 2003, 21:87-94.
28. Chichester CO, Fernández M, Minguell JJ Extracellular matrix gene expression by human bone marrow stroma and by marrow fibroblasts. Cell Adhes Commun 1993, 1:93-99.
29. Min JY, Sullivan MF, Yang Y, Zhang JP, Converso KL, Morgan JP, Xiao YF Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in post-infarcted pigs. Ann Thorac Surg 2002, 74:1568-1575.
30. Li SR, Qi XY, Hu FL, Zhang JQ, Wang TH, Dang Y, Meng CL, Liu HL, Li YX, Wu D, Dong J, Xun LY, Gao LH, Jin FC Mechanisms of improvement of left ventricle remodeling by trans-planting two kinds of autologous bone marrow stem cells in pigs. Chin Med J (Engl) 2008, 121:2403-2409.